News - Xenon Pharmaceuticals, Licensing

Filter

Popular Filters

Licensing deals between Xenon and Isis for XEN701, and Access and AMAG for MuGard

10-06-2013

USA-based Isis Pharmaceuticals (Nasdaq: ISIS) revealed that privately-held Canadian firm Xenon Pharmaceuticals…

Access PharmaceuticalsAMAG PharmaceuticalsIsis PharmaceuticalsLicensingMuGardNephrology and HepatologyOncologyPharmaceuticalXEN701Xenon Pharmaceuticals

Bristol-Myers Squibb signs up with another partner for daclatasvir, Merck & Co; latter expands deal with Xenon

23-04-2013

US pharma giant Merck & Co (NYSE: MRK) has entered into a non-exclusive agreement with drug major Bristol-Myers…

Anti-viralsBristol-Myers SquibbCardio-vasculardaclatasvirLicensingMerck & CoMK-5172PharmaceuticalResearchXenon Pharmaceuticals

Teva fleshes out restructuring plan; licenses Xenon pain drug for $376 million

12-12-2012

Teva Pharmaceutical Industries (NYSE: TEVA's new chief executive Jeremy Levin has outlined the company's…

CopaxoneFinancialGenericsLicensingPatentsPharmaceuticalResearchTeva Pharmaceutical IndustriesXenon Pharmaceuticals

Xenon in $646 million deal with Roche unit

10-01-2012

Canada based Xenon Pharmaceuticals, a privately-owned, clinical genetics-based drug discovery and development…

BiotechnologyGenentechLicensingNeurologicalPharmaceuticalResearchRocheXenon Pharmaceuticals

Back to top